0001652561 false --12-31 Q2 false Yes No 0001652561 2021-01-01 2021-06-30 0001652561 2021-08-16 0001652561 2021-06-30 0001652561 2020-12-31 0001652561 2021-04-01 2021-06-30 0001652561 2020-04-01 2020-06-30 0001652561 2020-01-01 2020-06-30 0001652561 us-gaap:CommonStockMember 2020-12-31 0001652561 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001652561 us-gaap:RetainedEarningsMember 2020-12-31 0001652561 us-gaap:NoncontrollingInterestMember 2020-12-31 0001652561 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001652561 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-06-30 0001652561 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001652561 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-06-30 0001652561 us-gaap:CommonStockMember 2021-06-30 0001652561 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001652561 us-gaap:RetainedEarningsMember 2021-06-30 0001652561 us-gaap:NoncontrollingInterestMember 2021-06-30 0001652561 us-gaap:CommonStockMember 2019-12-31 0001652561 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001652561 us-gaap:RetainedEarningsMember 2019-12-31 0001652561 us-gaap:NoncontrollingInterestMember 2019-12-31 0001652561 2019-12-31 0001652561 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001652561 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0001652561 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001652561 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-06-30 0001652561 us-gaap:CommonStockMember 2020-06-30 0001652561 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001652561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001652561 us-gaap:RetainedEarningsMember 2020-06-30 0001652561 us-gaap:NoncontrollingInterestMember 2020-06-30 0001652561 2020-06-30 0001652561 DQWS:DSwissHoldingLimitedMember DQWS:DSwissHKLimitedMember country:HK 2021-06-30 0001652561 DQWS:DSwissHoldingLimitedMember DQWS:DSwissSdnBhdMember country:MY 2021-06-30 0001652561 DQWS:DSwissBiotechMember country:MY 2021-06-30 0001652561 DQWS:DSwissHoldingLimitedMember 2021-01-01 2021-06-30 0001652561 DQWS:DSwissHKLimitedMember 2021-01-01 2021-06-30 0001652561 DQWS:DSwissSdnBhdMember 2021-01-01 2021-06-30 0001652561 DQWS:DSwissBiotechSdnBhdMember 2021-01-01 2021-06-30 0001652561 DQWS:ComputerAndSoftwareMember 2021-01-01 2021-06-30 0001652561 us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-06-30 0001652561 us-gaap:OfficeEquipmentMember 2021-01-01 2021-06-30 0001652561 DQWS:MotorVehicleMember 2021-01-01 2021-06-30 0001652561 DQWS:MalaysianRinggitExchangeMember 2021-06-30 0001652561 DQWS:MalaysianRinggitExchangeMember 2020-06-30 0001652561 DQWS:PeriodAverageMalaysianRinggitMember 2021-06-30 0001652561 DQWS:PeriodAverageMalaysianRinggitMember 2020-06-30 0001652561 DQWS:HongKongExchangeMember 2021-06-30 0001652561 DQWS:HongKongExchangeMember 2020-06-30 0001652561 DQWS:PeriodAverageHongKongMember 2021-06-30 0001652561 DQWS:PeriodAverageHongKongMember 2020-06-30 0001652561 DQWS:ManagementServicesAgreementIMember DQWS:DSwissHKLimitedMember 2016-06-26 2016-06-27 0001652561 DQWS:ComputerAndSoftwareMember 2021-06-30 0001652561 DQWS:ComputerAndSoftwareMember 2020-12-31 0001652561 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001652561 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001652561 us-gaap:OfficeEquipmentMember 2021-06-30 0001652561 us-gaap:OfficeEquipmentMember 2020-12-31 0001652561 DQWS:MotorVehiclesMember 2021-06-30 0001652561 DQWS:MotorVehiclesMember 2020-12-31 0001652561 country:SC 2021-01-01 2021-06-30 0001652561 country:SC 2020-01-01 2020-06-30 0001652561 country:HK 2021-01-01 2021-06-30 0001652561 country:HK 2020-01-01 2020-06-30 0001652561 country:MY 2021-01-01 2021-06-30 0001652561 country:MY 2020-01-01 2020-06-30 0001652561 DQWS:PeoplesRepublicOfChinaPRCMember 2021-01-01 2021-06-30 0001652561 DQWS:PeoplesRepublicOfChinaPRCMember 2020-01-01 2020-06-30 0001652561 2019-01-01 2019-06-30 0001652561 DQWS:UnitedStatesOfAmericaMember 2021-06-30 0001652561 DQWS:UnitedStatesOfAmericaMember 2021-01-01 2021-06-30 0001652561 DQWS:DSwissHKLimitedMember DQWS:HongKongMember 2021-01-01 2021-06-30 0001652561 DQWS:DSwissHKLimitedMember DQWS:HongKongMember 2021-06-30 0001652561 DQWS:DSwissSdnBhdandDSwissBiotechSdnBhdMember DQWS:MalaysiaMember srt:MinimumMember 2021-01-01 2021-06-30 0001652561 DQWS:DSwissSdnBhdandDSwissBiotechSdnBhdMember DQWS:MalaysiaMember srt:MaximumMember 2021-01-01 2021-06-30 0001652561 DQWS:DSwissSdnBhdandDSwissBiotechSdnBhdMember DQWS:MalaysiaMember 2021-06-30 0001652561 DQWS:DSwissSdnBhdandDSwissBiotechSdnBhdMember DQWS:MalaysiaMember 2021-01-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2021-04-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2020-04-01 2020-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2021-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2020-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2021-04-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2020-04-01 2020-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2021-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2020-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2021-04-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2020-04-01 2020-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2021-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2020-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:TwoCustomersMember 2021-04-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:TwoCustomersMember 2020-04-01 2020-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:TwoCustomersMember 2021-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:TwoCustomersMember 2020-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2021-01-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerAMember 2020-01-01 2020-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2021-01-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerBMember 2020-01-01 2020-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2021-01-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:CustomerCMember 2020-01-01 2020-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:ThreeCustomersMember 2021-01-01 2021-06-30 0001652561 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DQWS:ThreeCustomersMember 2020-01-01 2020-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:ThreeCustomersMember 2021-06-30 0001652561 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember DQWS:ThreeCustomersMember 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2021-04-01 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2020-04-01 2020-06-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2021-06-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2021-04-01 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2020-04-01 2020-06-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2021-06-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-04-01 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:TwoVendorsMember 2021-04-01 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:TwoVendorsMember 2020-04-01 2020-06-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:TwoVendorsMember 2021-06-30 0001652561 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember DQWS:TwoVendorsMember 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2021-01-01 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2020-01-01 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorAMember 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2021-01-01 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2020-01-01 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorBMember 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2021-01-01 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2020-01-01 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:VendorCMember 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-01-01 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:ThreeVendorsMember 2021-01-01 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:ThreeVendorsMember 2020-01-01 2020-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:ThreeVendorsMember 2021-06-30 0001652561 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember DQWS:ThreeVendorsMember 2020-06-30 0001652561 us-gaap:AccountingStandardsUpdate201602Member 2019-01-02 0001652561 2021-01-01 2021-03-31 0001652561 2021-03-31 0001652561 us-gaap:AccountingStandardsUpdate201602Member 2021-01-01 2021-06-30 0001652561 us-gaap:AccountingStandardsUpdate201602Member 2020-01-01 2020-12-31 0001652561 2020-01-01 2020-12-31 0001652561 2020-12-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended June 30, 2021

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________to _______________

 

Commission File Number 333-208083

 

DSwiss, Inc.

(Exact name of registrant issuer as specified in its charter)

 

Nevada   47-4215595
(State or other jurisdiction   (I.R.S. Employer
of incorporation or organization)   Identification No.)

 

Unit 18-11, 18-12 & 18-01, Tower A, Vertical Business Suite,

Avenue 3, Bangsar South, No.8 Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia

(Address of principal executive offices, including zip code)

 

Registrant’s phone number, including area code (603) 2770-4032

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Common Stock   DQWS   The OTC Market – Pink Sheets

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES ☒ NO ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

YES ☐ NO ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-accelerated Filer ☐ Smaller reporting company ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ☐ NO ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at Aug 16, 2021
Common Stock, $.0001 par value   206,904,600

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
PART I FINANCIAL INFORMATION  
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:  
  Condensed Consolidated Balance Sheets as of June 30, 2021(unaudited) and December 31, 2020 (audited) F-2
  Condensed Consolidated Statements of Operations and Comprehensive Income/Losses for the Three months and Six Months Ended June 30, 2021 and 2020 (unaudited) F-3
  Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Six Months Ended June 30, 2021 and 2020 (unaudited) F-4
  Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (unaudited) F-5
  Notes to the Condensed Consolidated Financial Statements F-6 - F-15
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 2-5
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 6
ITEM 4. CONTROLS AND PROCEDURES 6
PART II OTHER INFORMATION  
ITEM 1 LEGAL PROCEEDINGS 7
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 7
ITEM 3 DEFAULTS UPON SENIOR SECURITIES 7
ITEM 4 MINE SAFETY DISCLOSURES 7
ITEM 5 OTHER INFORMATION 7
ITEM 6 EXHIBITS 8
SIGNATURES 9

 

1

 

 

DSWISS, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

  Page
Condensed Consolidated Financial Statements  
   
Condensed Consolidated Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020 (audited) F-2
Condensed Consolidated Statements of Operations and Comprehensive Income/Losses for the Three months and Six months Ended June 30, 2021 and 2020 (unaudited) F-3
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Six Months Ended June 30, 2021 and 2020 (unaudited) F-4
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (unaudited) F-5
Notes to the Condensed Consolidated Financial Statements F-6 - F-15

 

F-1

 

 

PART I FINANCIAL INFORMATION

 

Item 1. Unaudited condensed consolidated financial statements:

 

DSWISS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of June 30, 2021, and December 31, 2020

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   

June 30,

2021

   

December 31,

2020

 
    Unaudited     Audited  
ASSETS                
CURRENT ASSETS                
Cash and cash equivalents   $ 163,334     $ 158,004  
Accounts receivable     59,042       9,146  
Other receivables, prepaid expenses and deposits     1,426       33,604  
Income tax receivables     623       434  
Inventories     23,005       37,995  
Total Current Assets     247,430       239,183  
                 
NON-CURRENT ASSETS                
Property and equipment, net     43,914       51,953  
Intangible assets, net     5,036       5,565  
Operating lease right -of-use, net     23,054       47,653  
Total Non-Current Assets     72,004       105,171  
                 
TOTAL ASSETS   $ 319,434     $ 344,354  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
CURRENT LIABILITIES                
Account payable   $ 471     $ 1,213  
Other payables and accrued liabilities     164,681       164,013  
Operating lease liability     23,609       48,114  
Amounts due to a director     152,334       155,437  
Finance lease liability     9,585       9,876  
Current tax liabilities     2,887       2,887  
Total Current Liabilities     353,567       381,540  
                 
NON- CURRENT LIABILITIES                
Finance lease liability     27,218       32,318  
Total Non-Current Liabilities     27,218       32,318  
                 
TOTAL LIABILITIES   $ 380,785     $ 413,858  
                 
STOCKHOLDERS’ EQUITY                
Preferred stock, $0.0001 par value, 200,000,000 shares authorized, None issued and outstanding     -       -  
Common stock, $0.0001 par value, 600,000,000 shares authorized, 206,904,600 and 206,904,600 shares issued and outstanding as of June 30, 2021 and December 31, 2020 respectively   $ 20,690     $ 20,690  
Additional paid-in capital     1,395,426       1,395,426  
Accumulated other comprehensive losses     (27,351 )     (28,177 )
Accumulated deficit     (1,469,970 )     (1,483,170 )
                 
TOTAL DSWISS, INC. STOCKHOLDERS’ EQUITY   $ (81,205 )   $ (95,231 )
NON-CONTROLLING INTEREST     19,854       25,727  
TOTAL STOCKHOLDERS’ EQUITY     (61,351 )     (69,504 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 319,434     $ 344,354  

 

See accompanying notes to condensed consolidated financial statements.

 

F-2

 

 

DSWISS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME/LOSSES

FOR THE THREE MONTHS AND SIX MONTHS ENDED June 30, 2021 AND 2020

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(Unaudited)

 

                                 
    Three months ended June 30     Six months ended June 30  
    2021     2020     2021     2020  
    $     $     $     $  
REVENUE     258,044       220,910       547,922       748,452  
                                 
COST OF REVENUE     (223,818 )     (169,796 )     (396,897 )     (577,332 )
                                 
GROSS PROFIT     34,226       51,114       151,025       171,120  
                                 
OTHER INCOME     3,810       7,587       5,773       8,791  
                                 
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES     (53,223 )     (10,385 )     (124,134 )     (87,264 )
                                 
OPERATING EXPENSES     (518 )     (23,975 )     (696 )     (45,387 )
                                 
FINANCE COST     (1,142 )     (2,219 )     (1,601 )     (2,760 )
                                 
LEASE EXPENSES     (6,791 )     (17,219 )     (21,217 )     (36,615 )
                                 
(LOSS)/PROFIT BEFORE INCOME TAX     (23,638 )     4,903       9,150       7,885  
                                 
TAXATION     -       -       -       -  
                                 
NET (LOSS)/PROFIT     (23,638 )     4,903       9,150       7,885  
Non-Controlling Interest     12,974       3,373       4,050       (8,574 )
Other comprehensive loss                                
- Foreign currency translation adjustment     524       19,420       826       18,852  
                                 
TOTAL COMPREHENSIVE (LOSS)/INCOME     (10,140 )     27,696       14,026       18,163  
                                 
NET LOSS/INCOME PER SHARE – BASIC AND DILUTED     -       -       -          
                                 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC AND DILUTED     206,904,600       206,904,600       206,904,600       206,904,600  

 

See accompanying notes to condensed consolidated financial statements.

 

F-3

 

 

DSWISS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(Currency expressed in United States Dollars (“US$”))

(unaudited)

 

Six months Ended June 30, 2021 (Unaudited)

 

                                             
    COMMON SHARES                                
    Number of shares     Amount    

ADDITIONAL
PAID-IN

CAPITAL

   

ACCUMULATED

COMPREHENSIVE
INCOME/(LOSS)

   

ACCUMULATED

(DEFICIT)

   

NON-

CONTROLLING INTEREST

   

TOTAL

EQUITY

 
Balance as of December 31, 2020 (audited)     206,904,600       20,690       1,395,426       (28,177 )     (1,483,170 )     25,727       (69,504 )
Foreign currency translation adjustment     -       -       -       826       -       (1,823 )     (997 )
Net income     -       -       -       -       13,200       (4,050 )     9,150  
Balance as of June, 2021 (unaudited)     206,904,600       20,690       1,395,426       (27,351 )     (1,469,970 )     19,854       (61,351 )

 

 

Six months Ended June 30, 2020 (Unaudited)

 

    COMMON SHARES                                
    Number of shares     Amount    

ADDITIONAL

PAID-IN

CAPITAL

   

ACCUMULATED

COMPREHENSIVE
INCOME/(LOSS)

   

ACCUMULATED

(DEFICIT)

   

NON-

CONTROLLING INTEREST

   

TOTAL

EQUITY

 
Balance as of December 31, 2019 (audited)     206,904,600       20,690       1,395,426       (34,564 )     (1,490,845 )     4,851       (104,442 )
Foreign currency translation adjustment     -       -       -       18,852       -       250       19,102  
Net income     -       -       -       -       (689 )     8,574       7,885  
Balance as of June, 2020 (unaudited)     206,904,600       20,690       1,395,426       (15,712 )     (1,491,534 )     13,675       (77,455 )

 

See accompanying notes to condensed consolidated financial statements

 

F-4

 

 

DSWISS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(Unaudited)

 

                 
    Six months ended June 30,  
    2021     2020  
CASH FLOWS FROM OPERATING ACTIVITIES:            
Profit before taxation   $ 9,150     $ 7,885  
Adjustments to reconcile net profit to net cash used in operating activities:                
Non-controlling interest     -       (8,574 )
Depreciation and amortization     32,591       31,699  
Amortization for intangible assets     519       520  
Changes in operating assets and liabilities:                
Account payable     (707 )     53,468  
Accounts receivable     (50,165 )     844  
Other payables and accrued liabilities     (2,220 )     (128,719 )
Inventories     13,872       (10,977 )
Lease liabilities     (23,088 )     -  
Prepaid expenses and deposits     32,178       96,966  
Cash generated from operations     12,130       43,112  
Tax paid     (202 )     (226 )
                 
Net cash generated from operating activities     11,928       42,886  
                 
CASH FLOWS FROM INVESTING ACTIVITY:                
Purchase of property and equipment     (2,886 )     (2,212 )
Net cash used in investing activity     (2,886 )     (2,212 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
Repayment to directors     (1,674 )     93  
Advance from related parties     275       -  
Repayment of finance lease     (4,148 )     (3,826 )
                 
Net cash used in financing activities     (5,547 )     (3,732 )
                 
Effect of exchange rate changes on cash and cash equivalents     1,835       12,646  
                 
Net increase in cash and cash equivalents     5,330       49,588  
Cash and cash equivalents, beginning of period     158,004       48,353  
CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 163,334     $ 97,941  
SUPPLEMENTAL CASH FLOWS INFORMATION                
Income taxes paid   $ (623 )   $ (115 )
Interest paid   $ 446     $ 2,760  

 

See accompanying notes to condensed consolidated financial statements.

 

F-5

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

1. DESCRIPTION OF BUSINESS AND ORGANIZATION

 

DSwiss, Inc. is organized as a Nevada limited liability company, incorporated on May 28, 2015. For the purposes of financial statement presentation, DSwiss, Inc. and its subsidiaries are herein referred to as “the Company” or “we”. The principal activity of the Company is premier biotech-nutraceutical, beauty supplies, and medical consumables supplies. The company sells medical consumable supplies, food supplements, skincare, and other related beauty products in Malaysia and around the ASEAN region. We are globally recognized Turnkey Private Label Manufacturing Services for nutraceutical and skincare OEM/ODM products.

 

Our professionals manage from custom formulation of scientifically proven and naturally effective, sourcing raw materials, production, quality control, stability, and safety test, clinical testing by third-party labs, packaging, and shipping, including import and export.

 

Our manufacturing facilities which compliant with GMP (Good Manufacturing Practice), FDA (Food Drug Association), HACCP (Hazard Analysis and Critical Control Point), JAKIM HALAL, and Mesti.

 

The accompanying unaudited condensed consolidated financial statements of DSwiss, Inc. at June 30, 2021 and 2020 have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended December 31, 2020. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the periods ended June 30, 2021 and 2020 presented are not necessarily indicative of the results to be expected for the full year. The December 31, 2020 balance sheet has been derived from our audited financial statements included in our annual report on Form 10-K for the year ended December 31, 2020.

 

We have historically conducted our business through DSwiss Sdn Bhd, a private limited liability company, incorporated in Malaysia. DSwiss Holding Limited, incorporated in Seychelles, is an investment holding company with 100% equity interest in DSwiss (HK) Limited, a company incorporated in Hong Kong, which subsequent hold 100% equity interest in DSwiss Sdn. Bhd. On August 31, 2015, DSwiss, Inc. was restructured to be the holding company parent to, and succeed to the operations of, DSwiss Holding Limited. The former unit holder of DSwiss Holding Limited became the unit holder of DSwiss, Inc. and DSwiss Holding Limited became a wholly-owned subsidiary of DSwiss, Inc. This transaction was accounted for as a transaction among entities under common control and the assets, liabilities, revenues and expenses of DSwiss Holding Limited were carried over to and combined with DSwiss, Inc. at historical cost, and as if the transfer occurred at the beginning of the period. Prior periods have been retrospectively adjusted for comparative purposes.

 

We have invested in DSwiss Biotech Sdn Bhd, a Company incorporated in Malaysia, and owned 40% equity interest.

 

The Company, through its subsidiaries and its variable interest entities (“VIEs”), mainly supplies high quality beauty products. Details of the Company’s subsidiaries and associates:

 

    Company name   Place and date of incorporation   Particulars of
issued capital 		  Principal activities  

Proportional of ownership interest

and voting power

held

 
                       
1.   DSwiss Holding Limited  

Seychelles, May 28, 2015

  1 share of ordinary share of US$1 each   Investment holding     100 %
                         
2.   DSwiss (HK) Limited  

Hong Kong, May 28, 2015

  1 share of ordinary share of HK$1 each   Supply of beauty products     100 %
                         
3.   DSwiss Sdn Bhd  

Malaysia, March 10, 2011

  2 shares of ordinary share of RM 1 each   Supply of beauty products     100 %
                         
4.   DSwiss Biotech Sdn Bhd(1)  

Malaysia, March 17, 2016

  250,000 shares of ordinary share of RM 1 each   Supply of biotech products     40 %

 

(1) Based on the contractual arrangements between the Company and other investors, the Company has the power to direct the relevant activities of these entities unilaterally, and hence the Company has control over these entities.

 

F-6

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

2. GOING CONCERN UNCERTAINTIES

 

The accompanying financial statements have been prepared using the going concern basis of accounting, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

 

As of June 30, 2021, the Company suffered an accumulated deficit of $1,469,970 and net current liabilities of $353,567 for period ended June 20, 2021. The continuation of the Company as a going concern through June 30, 2021 is dependent upon improving the profitability and the continuing financial support from its major stockholders. Management believes the existing major shareholders or external financing will provide the additional cash to meet the Company’s obligations as they become due.

 

These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result in the Company not being able to continue as a going concern.

 

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

 

Basis of consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its subsidiaries in which the Company is the primary beneficiary. All inter-company accounts and transactions have been eliminated upon consolidation.

 

Use of estimates

 

In preparing these consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets, and revenues and expenses during the periods reported. Actual results may differ from these estimates.

 

Revenue recognition

 

The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.

 

Revenue from trading of retail goods is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company’s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management’s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.

 

The Company mainly derives its revenue from the sale of healthy food products. Generally, the Company recognizes revenue when products are sold and accepted by the customers and there are no continuing obligations to the customer.

 

Cost of revenue

 

Cost of revenue includes the purchase cost of retail goods for re-sale to customers and packing materials (such as boxes). It excludes purchasing and receiving costs, inspection costs, warehousing costs, internal transfer costs and other costs of distribution network in cost of revenues.

 

F-7

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

Selling and distribution expenses

 

Selling and distribution expenses are primarily comprised of travelling and accommodation, transportation fees such as petrol, toll and parking and shipping and handling fees.

 

Cash and cash equivalents

 

The Company consider all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalent.

 

Inventories

 

Inventories consisting of products available for sell, are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks and rewards of the products purchased. Write downs are recorded in cost of revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income.

 

Property and equipment

 

Property and equipment are stated at cost less accumulated depreciation and impairment. Depreciation of plant, equipment and software are calculated on the straight-line method over their estimated useful lives or lease terms generally as follows:

 

Classification   Estimated useful lives
Computer and software   5 years
Furniture and fittings   5 years
Office equipment   10 years
Motor vehicle   5 years

 

Intangible assets

 

Intangible assets are stated at cost less accumulated amortization. Intangible assets represented the registration costs of trademarks in Hong Kong, and Malaysia, which are amortized on a straight-line basis over a useful life of ten years.

 

The Company follows ASC Topic 350 in accounting for intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets’ carrying amounts. There was no impairment losses recorded on intangible assets for the six months ended June 30, 2021.

 

Leases

 

Prior to November 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases. Effective November 1, 2019, the Company adopted the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The implementation of ASC 842 did not have a material impact on the Company’s consolidated financial statements and did not have a significant impact on our liquidity. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods. (see Note 11).

 

Income taxes

 

Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

 

The Company conducts major businesses in Malaysia and Hong Kong, and is expanding to China. The Company is subject to tax in these jurisdiction. As a result of its business activities, the Company will file tax returns that are subject to examination by the foreign tax authority.

 

F-8

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

Net (loss)/income per share

 

The Company calculates net (loss)/income per share in accordance with ASC Topic 260, “Earnings per Share.” (loss)/income per share is computed by dividing the net (loss)/income by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed similar to (loss)/income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

 

Foreign currencies translation

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the Condensed Consolidated Statements of Operations and Comprehensive Income.

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the Company’s subsidiaries and VIEs in Malaysia, Hong Kong, maintains their books and record in their local currency, Ringgits Malaysia (“RM”), Hong Kong Dollars (“HK$”), respectively, which is functional currency as being the primary currency of the economic environment in which the entity operates.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity.

 

Translation of amounts from RM into US$1 and HK$ into US$1 has been made at the following exchange rates for the respective periods:

 

   

As of and for the six months ended

June 30,

 
    2021     2020  
             
Period-end RM : US$1 exchange rate     4.15       4.28  
Period-average RM : US$1 exchange rate     4.09       4.25  
Period-end HK$ : US$1 exchange rate     7.77       7.75  
Period-average HK$ : US$1 exchange rate     7.77       7.76  

 

F-9

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Fair value of financial instruments:

 

The carrying value of the Company’s financial instruments: cash and cash equivalents, trade receivables, deposits, trade payable, other payables, and accounts payable approximate at their fair values because of the short-term nature of these financial instruments.

 

The Company also follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

 

Level 1: Observable inputs such as quoted prices in active markets;

 

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

 

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

Segment reporting

 

ASC Topic 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. For the six months ended June 30, 2021, the Company operates in four reportable operating segment in Malaysia, and Hong Kong.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

 

F-10

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

4. VIE STRUCTURE AND ARRANGEMENTS

 

On June 27, 2016, DSwiss (HK) Limited (“DSHK”) entered into a Management Services Agreement (the “Management Services Agreement I”) which entitles DSHK to substantially entitled to all of the economic benefits of DSwiss Biotech Sdn Bhd (“DSBT”) in consideration of services provided by DSHK to DSBT. Pursuant to the Management Services Agreement I, DSHK has the exclusive right to provide to DSBT management, financial and other services related to the operation of DSBT’s business, and DSBT is required to take all commercially reasonable efforts to permit and facilitate the provision of the services provided by DSHK. As compensation for providing the services, DSHK is entitled to receive a fee from DSBT, upon demand, equal to 100% of the annual net profits of DSBT during the term of the Management Services Agreement I. DSHK may also request, on ad hoc basis, quarterly payments of the aggregate fee, which payments will be credited against DSBT’s future payment obligations.

 

The Management Services Agreement I also provides DSHK, or its designee, with a right of first refusal to acquire all or any portion of the equity of DSBT upon any proposal by the sole shareholder of DSBT to transfer such equity. In addition, at the sole discretion of DSHK, DSBT is obligated to transfer to DSHK, or its designee, any part or all of the business, personnel, assets and operations of DSBT which may be lawfully conducted, employed, owned or operated by DSHK, including:

 

(a) business opportunities presented to, or available to DSBT may be pursued and contracted for in the name of DSHK rather than DSBT, and at its discretion, DSHK may employ the resources of DSBT to secure such opportunities;

 

(b) any tangible or intangible property of DSBT, any contractual rights, any personnel, and any other items or things of value held by DSBT may be transferred to DSHK at book value;

 

(c) real property, personal or intangible property, personnel, services, equipment, supplies and any other items useful for the conduct of the business may be obtained by DSHK by acquisition, lease, license or otherwise, and made available to DSBT on terms to be determined by agreement between DSHK and DSBT;

 

(d) contracts entered into in the name of DSBT may be transferred to DSHK, or the work under such contracts may be subcontracted, in whole or in part, to DSHK, on terms to be determined by agreement between DSHK and DSBT; and

 

(e) any changes to, or any expansion or contraction of, the business may be carried out in the exercise of the sole discretion of DSHK, and in the name of and at the expense of, DSHK; provided, however, that none of the foregoing may cause or have the effect of terminating (without being substantially replaced under the name of DSHK) or adversely affecting any license, permit or regulatory status of DSBT.

 

In addition, DSHK entered into certain agreements with Jervey Choon, (the “DSBT shareholder”), including

 

(i) a Call Option Agreement allowing DSHK to acquire the shares of DSBT as permitted by Malaysia laws;
   
(ii) a Shareholders’ Voting Rights Proxy Agreement that provides DSHK with the voting rights of the DSBT; and
   
(iii) an Equity Pledge Agreement that pledges the shares in DSBT.

 

This VIE structure provides DSHK, a wholly-owned subsidiary of DSwiss Holding Limited, which is the wholly-owned subsidiary of DSwiss Inc, with control over the operations and benefits of DSBT without having a direct equity ownership in DSBT.

 

F-11

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

5. STOCKHOLDERS’ EQUITY

 

As of June 30, 2021, the Company had a total of 206,904,600 of its common stock issued and outstanding. There are no shares of preferred stock issued and outstanding.

 

6. PROPERTY AND EQUIPMENT

 

   

June 30, 2021

    December 31, 2020  
Computers and software   $ 97,226     $ 96,508  
Furniture and fittings     6,144       6,144  
Office equipment     13,281       11,113  
Motor vehicles     79,054       79,054  
Total property and equipment   $ 195,705     $ 192,819  
Accumulated depreciation     (147,912 )     (138,371 )
Effect of translation exchange     (3,879 )     (2,495 )
Property and equipment, net   $ 43,914     $ 51,953  

 

Depreciation expense for the three months and six months ended June 30, 2021 were $4,817 and $9,553 respectively.

 

Depreciation expense for the three months and six months ended June 30, 2020 were $4,828 and $10,074 respectively.

 

7. INTANGIBLE ASSETS

 

   

June 30, 2021

    December 31, 2020  
Trademarks   $ 12,077     $ 12,077  
Amortization     (6,620 )     (6,101 )
Effect of translation exchange     (421 )     (411 )
Intangible assets, net   $ 5,036     $ 5,565  

 

Amortization for the three months and six months ended June 30, 2021 was $519 and $519 respectively.

 

Amortization for the three months and six months ended June 30, 2020 was $260 and $520 respectively.

 

8. OTHER RECEIVABLES, PREPAID EXPENSES AND DEPOSITS

 

   

June 30, 2021

    December 31, 2020  
Prepaid expenses   $ 1,426     $ 1,470  
Deposits     -       32,134  
Total prepaid expenses and deposits   $ 1,426     $ 33,604  

 

9. INVENTORIES

 SCHEDULE OF INVENTORIES

   

June 30, 2021

    December 31, 2020  
Finished goods, at cost   $ 23,005     $ 37,995  
Total inventories   $ 23,005     $ 37,995  

 

10. OTHER PAYABLES AND ACCRUED LIABILITIES

 

   

June 30, 2021

    December 31, 2020  
Other payables   $ 137,310     $ 120,521  
Accrued audit fees     11,950       18,831  
Accrued other expenses     12,920       20,911  
Accrued professional fees     2,500       3,750  
Total payables and accrued liabilities   $ 164,680     $ 164,013  

 

F-12

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

11. FINANCE LEASE LIABILITY

 

The Company purchased a motor vehicle under a finance lease agreement with the effective interest rate of 2.72% per annum, due through June, 2024, with principal and interest payable monthly. The obligation under the finance lease is as follows:

 

    As of June 30,     As of December 31,  
    2021     2020  
Finance lease   $ 40,105     $ 46,490  
Less: interest expense     (3,302 )     (4,296 )
Net present value of finance lease     36,803       42,194  
                 
Current portion     9,585       9,876  
Non-current portion     27,218       32,318  
Total   $ 36,803     $ 42,194  

 

As of June 30, 2021 the maturities of the finance lease for each of the years are as follows:

               
2021           9,585  
2022           8,675  
2023           9,079  
2024           9,464  
Total         $ 36,803  

 

12. AMOUNT DUE TO A DIRECTOR

 

As of June 30, 2021 and December 31, 2020, a director of the Company advanced $152,334 and $155,437, respectively to the Company, which is unsecured, interest-free with no fixed repayment term, for working capital purpose.

 

13. INCOME TAXES

 

For the six months ended June 2021 and 2020, the local (United States) and foreign components of (loss)/income before income taxes were comprised of the following:

   

For the six months ended

   

For the six months ended

 
    2021     2020  
             
Tax jurisdictions from:                
- Local   $ (17,845 )   $ (12,562 )
- Foreign, representing                
Seychelles     (1,428 )     (1,593 )
Hong Kong     (2,779 )     18,234  
Malaysia     31,202       14,751  
PRC     -       (10,945 )
                 
Profit before income tax   $ 9,150     $ 7,885  

 

The provision for income taxes consisted of the following:

 

   

For the six

months ended

   

For the six

months ended

 
    2021     2020  
Current:                      
- Local   $ -     $ -  
- Foreign     -       -  
                 
Deferred:                
- Local     -       -  
- Foreign     -       -  
                 
Income tax expense   $ -     $ -  

 

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company has subsidiaries that operate in various countries: United States, Seychelles, Hong Kong, Malaysia and PRC that are subject to taxes in the jurisdictions in which they operate, as follows:

 

United States of America

 

The Company is registered in the State of Nevada and is subject to the tax laws of the United States of America. As of June 30, 2021, the operations in the United States of America incurred $403,394  of cumulative net operating losses which can be carried forward to offset future taxable income, at the tax rate of 21%. The net operating loss carry forwards begin to expire in 2038, if unutilized. The Company has provided for a full valuation allowance of $84,712 against the deferred tax assets on the expected future tax benefits from the net operating loss carry forwards as the management believes it is more likely than not that these assets will not be realized in the future.

 

Seychelles

 

Under the current laws of the Seychelles, DSwiss Holding Limited is registered as an international business company which governs by the International Business Companies Act of Seychelles and there is no income tax charged in Seychelles.

 

Hong Kong

 

DSwiss (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income tax rate of 16.5% on its assessable income. As of June 30, 2021, the operations in the Hong Kong incurred $624,994 of cumulative net operating losses which can be carried forward to offset future taxable income, at the tax rate of 16.5%. The Company has provided for a full valuation allowance of $103,124 against the deferred tax assets on the expected future tax benefits from the net operating loss carry forwards as the management believes it is more likely than not that these assets will not be realized in the future.

 

Malaysia

 

DSwiss Sdn Bhd and DSwiss Biotech Sdn Bhd are subject to Malaysia Corporate Tax, which is charged at the statutory income tax rate range from 17% to 24% on its assessable income. As of June 30, 2021, the operations in the Malaysia incurred $441,491 of cumulative net operating losses which can be carried forward to offset future taxable income, at the tax rate of 17%. The Company has provided for a full valuation allowance of $75,002 against the deferred tax assets on the expected future tax benefits from the net operating loss carry forwards as the management believes it is more likely than not that these assets will not be realized in the future.

 

F-13

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

14. CONCENTRATIONS OF RISK

 

The Company is exposed to the following concentrations of risk:

 

(a) Major customers

 

For three months ended June 30, 2021 and 2020, the customers who accounted for 10% or more of the Company’s revenues and its accounts receivable balance at period-end are presented as follows:

 

    2021     2020     2021     2020     2021     2020  
    Revenues    

Percentage
of revenues

   

Accounts
receivable, trade

 
                                     
Customer A   $ 11,709     $ 168,550       5 %     72 %   $ -       -  
Customer B   $ 108,534       -       42 %     - %     -       -  
Customer C   $ 91,714     $ -       36 %     - %   $ 43,562       -  
    $ 211,957     $ 168,550       83 %     72 %   $ 43,562       -  

 

For six months ended June 30, 2021 and 2020, the customers who accounted for 10% or more of the Company’s revenues and its accounts receivable balance at period-end are presented as follows:

 

    2021     2020     2021     2020     2021     2020  
    Revenues    

Percentage
of revenues

   

Accounts
receivable, trade

 
                                     
Customer A   $ 46,154     $ 227,731       8 %     30 %   $ -       -  
Customer B   $ 281,913     $ -       51 %     - %     -       -  
Customer C   $

136,227

    $ 114,561       25 %     15 %   $

43,562

      -  
    $ 464,294     $ 342,292       84 %     45 %   $ 43,562       -  

 

(b) Major vendors

 

For three months ended June 30, 2021 and 2020, the vendors who accounted for 10% or more of the Company’s purchases and its accounts payable balance at period-end are presented as follows:

 

    2021     2020     2021     2020     2021     2020  
    Purchase    

Percentage
of purchases

   

Accounts
payable, trade

 
                                     
Vendor A   $ 12,380     $ 92,746       6 %     53 %   $ -       -  
Vendor B   $ 129,203     $ 40,780       58 %     23 %   $ -       -  
    $ 141,583     $ 133,526       64 %     76 %   $ -       -  

 

For six months ended June 30, 2021 and 2020, the vendors who accounted for 10% or more of the Company’s purchases and its accounts payable balance at period-end are presented as follows:

 

    2021     2020     2021     2020     2021     2020  
    Purchase    

Percentage
of purchases

   

Accounts
payable, trade

 
                                     
Vendor A   $ 29,295     $ 206,815       7 %     35 %   $ -       -  
Vendor B   $ 258,625     $ 120,004       65 %     20 %   $ -       -  
Vendor C   $ 3,833     $ 85,095       1 %     15 %   $ -       -  
    $ 318,425     $ 411,914       73 %     70 %   $ -       -  

 

All vendors are located in Malaysia.

 

(c) Credit risk

 

Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

 

(d) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain stable, therefore there is a possibility that the Company could post the same amount of income for two comparable periods and because of the fluctuating exchange rate actually post higher or lower income depending on exchange rate of RM converted to US$ and HK$ converted into US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

F-14

 

 

DSWISS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(UNAUDITED)

 

15. LEASE RIGHT-OF-USE ASSET AND LEASE LIABILITIES

 

The Company officially adopted ASC 842 for the period on and after January 1, 2019 as permitted by ASU 2016-02. ASC 842 originally required all entities to use a “modified retrospective” transition approach that is intended to maximize comparability and be less complex than a full retrospective approach. On July 30, 2018, the FASB issued ASU 2018-11 to provide entities with relief from the costs of implementing certain aspects of the new leasing standard, ASU 2016-02 of which permits entities may elect not to recast the comparative periods presented when transitioning to ASC 842. As permitted by ASU 2018-11, the Company elect not to recast comparative periods, thusly.

 

As of January 1, 2019, the Company recognized approximately US$136,308, lease liability as well as right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. Lease liabilities are measured at present value of the sum of remaining rental payments as of January 1, 2019, with discounted rate of 4.47% adopted from Public Bank Berhad’s base lending rate as a reference for discount rate.

 

A single lease cost is recognized over the lease term on a generally straight-line basis. All cash payments of operating lease cost are classified within operating activities in the statement of cash flows.

 

The operating lease right and lease liability as follow:

 

As of June 30, 2021, operating lease right of use asset as follow:

 

Right-Of-Use Assets        
As of January 1, 2021   $ 47,653  
Amortization for the three months ended March 31, 2021     (11,744 )
Foreign exchange translation     (480 )
Balance as of March 31, 2021   $ 35,429  
Amortization for the three months ended June 30, 2021     (11,875 )
Foreign exchange translation     (500 )
Balance as of June 30, 2021   $ 23,054  

 

For the three months ended June 30, 2021 and 2020, the amortization of the operating lease right of use asset are $11,875 and $9,440 respectively.

 

As of June 30, 2021, operating lease liability as follow:

 

 

Lease Liability        
As of January 1, 2021   $ 48,114  
Imputed interest     447  
Gross repayment     (12,241 )
Foreign exchange translation     (34 )
Balance as of March 31, 2021   $ 36,286  
Imputed interest     311  
Gross repayment     (12,114 )
Foreign exchange translation     (874 )
Balance as of June 30, 2021   $ 23,609  
Less: lease liability current portion     23,609  

 

Maturities of operating lease obligation as follow:

 

Year ending      
December 31, 2021     23,609  
Total   $ 23,609  

 

Other information:

 

    Period ended
June 30, 2021 		    Year ended
December 31, 2020 		 
    (Unaudited)     (Audited)  
Cash paid for amounts included in the measurement of lease liabilities:                
Operating cash flow from operating lease   $ 23,195     $ 45,312  
Right-of-use assets obtained in exchange for operating lease liabilities     23,054       47,653  
Remaining lease term for operating lease (years)     1       1  
Weighted average discount rate for operating lease     4.47 %     4.47 %

 

Lease expenses were $23,195 for the period ended June 30, 2021, respectively while lease expenses were $46,094 for the year ended December 31, 2020

 

16. SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after June 30, 2021 up through the date the Company issued the consolidated financial statements.

 

17. SIGNIFICANT EVENTS

 

During the fiscal year, the World Health Organization declared the Coronavirus (COVID-19) outbreak to be a pandemic, which has caused severe global social and economic disruptions and uncertainties, including markets where the Company operates.

 

The Company considers this outbreak as non-adjusting-events. The consequences brought about by Covid-19 continue to evolve and whilst the Company actively monitoring and managing its operations to respond to these changes, the Company does not consider it practicable to provide any quantitative estimate on the potential impact it may have on the Company.

 

F-15

 

 

Item 2. Management’s discussion and analysis of financial condition and results of operations

 

The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended December 31, 2020 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Form 10-Q.

 

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We strongly encourage investors to carefully read the factors described in our Form S-1 Amendment No.8, dated July 20, 2016 in the section entitled “Risk Factors” for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited Condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.

 

Company Overview

 

DSwiss, Inc., a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on May 28, 2015. DSwiss Holding Limited owns 100% of DSwiss (HK) Limited, a Hong Kong Company, which owns 100% of DSwiss Sdn Bhd, the operating Malaysia Company of which is described below. In 2016, DSwiss (HK) Limited invested in DSwiss Biotech Sdn Bhd, incorporated in Malaysia, and owned 40% equity interest.

 

DSwiss is the leading corporation for premier nutraceutical biotechnology in USA, and has gone into Asian countries such as China, Hong Kong, Singapore, Thailand, and Malaysia with our high quality functional health supplement, skin care solution, wellness products and private labelled supplies turnkey provider (OEM/ODM). Our unique and innovative patented biotechnology, natural ingredients into products & services that has been proven to give better, faster and visible positive results to the end user including health improvement, slimming, anti-aging and beauty effects.

 

Currently, we are fulfilling in Talent Development, product research and development, and providing Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services into functional food and beauty product of which is currently under research and development with Malaysia biotech and research professionals. Our professionals manage from custom formulation of scientifically-proven and naturally-effective, sourcing raw materials, production, quality control, stability and safety test, clinical testing by third-party labs, packaging and shipping including import and export, all licenses needed so customer can concentrate on what they should do. In 2020, with our experience and expertise, we have successfully expanded our client base in OEM/ODM services and developed products and Business-to-business (B2B) DNA genotyping private label services that exceed the clients’ expectation.

 

DSwiss has continuously expanding through launching health and beauty projects to provide premier experiences to the customers. DSwiss has shown a solid growth and is set to advance the biotechnology industry to drive nutraceutical and skincare biotechnology growth.

 

At this time, we operate exclusively online through our website: http://www.dswissbeauty.com.

 

Products which meet the definition of a functional food and cosmetics related products need to be registered or notified with the Drug Control Authority (DCA), Ministry of Health Malaysia. Manufacturing, marketing, importation and the sale of unregistered products is a violation of the Drug Control Regulations and Cosmetics Act 1984 of Malaysia and enforcement action can be taken.

 

At DSwiss, research and development is an ongoing effort whose purpose is to ensure our products on the forefront of quality and effectiveness. Equipped with state of the art machinery, our innovative research and development team are constantly exploring on new development and product lines that will enable us to provide the highest quality standard and remain competitive in the industry.

 

DSwiss’s products are certified and approved by the Ministry of Health (“MOH”) Malaysia. Due to the stringent requirements from MOH Malaysia, we strive to upkeep the highest possible standard in our products to provide assurance and as a prove of our continuing commitment to providing quality products.

 

Our expected growth is planned to occur primarily through the implementation of our social media marketing strategy. DSwiss already has a strong relationship with new retail tech company (eg. Facebook, E-Marketplace). The global presence social media has helped provide to us has been an invaluable resource, and as we continue to expand our business operations and spread our brand awareness, we intend to primarily utilize social media to reach our customers. The benefits of social media are countless, but perhaps the most imperative to our future success is our ability to connect with customers directly, to receive their feedback almost instantaneously. On that note, the feedback we have received from our clients has been overwhelmingly positive, which has helped us to create a robust brand image.

 

While DSwiss has been focused almost exclusively upon pursuing operations within Asia, we do have plans to expand outward and become a household name across the world. Our strategy to do so going forward is by forming partnerships with local companies in various countries that may be willing to stock our products or promote them to their own customers. We believe that by forging strategic relationships and partnerships we can expand our operations across the globe at a greater pace and with greater certainty than we would if we tried to expand on our own.

 

Results of Operation

 

For the Three Months and Six Months Ended June 30, 2021 and June 30, 2020.

 

For the three and six months ended June 30, 2021, we realized revenue in the amount of $258,044 and $547,922, while for the three and six months ended June 30, 2020, we realized revenues in the amount of $220,910 and $748,452. Our gross profits for the three and six months ended June 30, 2021 were $34,226 and $151,025, which is less than $51,114 and $171,120 for the three and six months ended June 30, 2020. We believe that in order to retain and maintain more customers in the future we must increase our marketing efforts and or develop new products.

 

*Our gross margins may not be comparable to those of other entities, since some entities include all the costs related to their distribution network in cost of revenue. Our cost of revenue includes only the purchase cost of products and packing materials, and does not include any allocation of inbound freight charges, purchasing and receiving costs, inspection costs, warehousing costs, internal transfer costs, and the other costs associated with the distribution network.

 

2

 

 

Our net loss for three months ended June 30, 2021 was $23,638 and our net profit for six months ended June 30, 2021 was $9,150, while the net profit for three months and six months ended June 30, 2020 and 2020 was $4,903 and $7,885. We attribute this increase in profit due to increase in product sales and market share.

 

The increases in general and administrative expenses are a result of advertising and compliance costs as a public company.

 

Liquidity and Capital Resources

 

For the six months ended June 30, 2021, we had cash and cash equivalents of $163,334. We have positive operating cash flows and our working capital has been and will continue to be significant. We need to meet our working capital requirements and to make capital investments in connection with ongoing operations. The Company expects its current capital resources to meet our basic operating requirements for approximately twelve months.

 

Operating Activities

 

For the six months ended June 30, 2021 and 2020, net cash generated from operating activities was $11,928 and $42,886 in the prior year. The operating cash flow performance primarily reflects increase in accounts receivable to the prior period.

 

Investing Activities

 

For the six months ended June 30, 2021, net cash used in investing activities was $2,886, reflecting the cost in purchase of property and equipment. For the six months ended June 30, 2020, net cash used in investing activities was $2,212.

 

Financing Activities

 

For the six months ended June 30, 2021, net cash used for financing activities was $5,547 resulted from the repayment of hire purchase, repayment to directors and advance from related parties. For the six months ended June 30, 2020, net cash used for financing activities was $3,732 resulted from the repayment of finance lease.

 

3

 

 

Capital Expenditures

 

Our capital expenditures primarily relate to the acquisition of property and equipment. There is a $2,886 used to purchase the computer and software and office equipment for the six months periods ended June 30, 2021. Our capital expenditure for the six months periods ended June 30, 2020 was $2,212.

 

Credit Facilities

 

We do not have any credit facilities or other access to bank credit.

 

Contractual Obligations, Commitments and Contingencies

 

We currently have a lease agreement in place with respect to office premises in Malaysia to commence our business operations.

 

Off-balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders as of June 30, 2021.

 

4

 

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations

 

Additional Information

 

VIE STRUCTURE AND ARRANGEMENTS

 

On June 27, 2016, DSwiss (HK) Limited (“DSHK”) entered into a Management Services Agreement (the “Management Services Agreement I”) which entitles DSHK to substantially entitled to all of the economic benefits of DSwiss Biotech Sdn Bhd (“DSBT”) in consideration of services provided by DSHK to DSBT. Pursuant to the Management Services Agreement I, DSHK has the exclusive right to provide to DSBT management, financial and other services related to the operation of DSBT’s business, and DSBT is required to take all commercially reasonable efforts to permit and facilitate the provision of the services provided by DSHK. As compensation for providing the services, DSHK is entitled to receive a fee from DSBT, upon demand, equal to 100% of the annual net profits of DSBT during the term of the Management Services Agreement I. DSHK may also request ad hoc quarterly payments of the aggregate fee, which payments will be credited against DSBT’s future payment obligations.

 

The Management Services Agreement I also provides DSHK, or its designee, with a right of first refusal to acquire all or any portion of the equity of DSBT upon any proposal by the sole shareholder of DSBT to transfer such equity. In addition, at the sole discretion of DSHK, DSBT is obligated to transfer to DSHK, or its designee, any part or all of the business, personnel, assets and operations of DSBT which may be lawfully conducted, employed, owned or operated by DSHK, including:

 

(a) business opportunities presented to, or available to DSBT may be pursued and contracted for in the name of DSHK rather than DSBT, and at its discretion, DSHK may employ the resources of DSBT to secure such opportunities;

 

(b) any tangible or intangible property of DSBT, any contractual rights, any personnel, and any other items or things of value held by DSBT may be transferred to DSHK at book value;

 

(c) real property, personal or intangible property, personnel, services, equipment, supplies and any other items useful for the conduct of the business may be obtained by DSHK by acquisition, lease, license or otherwise, and made available to DSBT on terms to be determined by agreement between DSHK and DSBT;

 

(d) contracts entered into in the name of DSBT may be transferred to DSHK, or the work under such contracts may be subcontracted, in whole or in part, to DSHK, on terms to be determined by agreement between DSHK and DSBT; and

 

(e) any changes to, or any expansion or contraction of, the business may be carried out in the exercise of the sole discretion of DSHK, and in the name of and at the expense of, DSHK; provided, however, that none of the foregoing may cause or have the effect of terminating (without being substantially replaced under the name of DSHK) or adversely affecting any license, permit or regulatory status of DSBT.

 

In addition, DSHK entered into certain agreements with Jervey Choon, (the “DSBT shareholder”), including

 

(i) a Call Option Agreement allowing DSHK to acquire the shares of DSBT as permitted by Malaysia laws;
   
(ii) a Shareholders’ Voting Rights Proxy Agreement that provides DSHK with the voting rights of the DSBT; and
   
(iii) an Equity Pledge Agreement that pledges the shares in DSBT.

 

This VIE structure provides DSHK, a wholly-owned subsidiary of DSwiss Holding Limited, which is the wholly-owned subsidiary of DSwiss Inc, with control over the operations and benefits of DSBT without having a direct equity ownership in DSBT.

 

5

 

 

Item 3 Quantitative and Qualitative Disclosures About Market Risk.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

Item 4 Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures:

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of June 30, 2016. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2021, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of June 30, 2021, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

Changes in Internal Control over Financial Reporting:

 

There were no changes in our internal control over financial reporting during the quarter ending June 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

6

 

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We know of no material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest adverse to us.

 

Item 1A. Risk Factors.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

7

 

 

ITEM 6. Exhibits

 

Exhibit No.   Description
31.1   Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer*
32.1   Section 1350 Certification of principal executive officer *
101.INS   XBRL Instance Document*
101.SCH   XBRL Schema Document*
101.CAL   XBRL Calculation Linkbase Document*
101.DEF   XBRL Definition Linkbase Document*
101.LAB   XBRL Label Linkbase Document*
101.PRE   XBRL Presentation Linkbase Document*

 

* Filed herewith.

 

8

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

DSWISS, INC.
(Name of Registrant)

 

Date: August 16, 2021

   
     
  By: /s/ Leong Ming Chia
  Title:

President, Chief Executive Officer,

Chief Financial Officer, Treasurer, Secretary and Director

    (Principal Executive Officer, Principal Financial Officer)

 

9

 

Dswiss (PK) (USOTC:DQWS)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Dswiss (PK) Charts.
Dswiss (PK) (USOTC:DQWS)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Dswiss (PK) Charts.